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Abstract
It has now been a decade since the first discovery of the intracellular Smad proteins, the
downstream signalling molecules of one of the most important growth factor families in the animal
kingdom, the transforming growth factor beta (TGF-beta) superfamily. In the ovary, several TGF-
beta superfamily members are expressed by the oocyte, granulosa and thecal cells at different
stages of folliculogenesis, and they signal mainly through two different Smad pathways in an
autocrine/paracrine manner. Defects in the upstream signalling cascade molecules, the ligands and
receptors, are known to have adverse effects on ovarian organogenesis and folliculogenesis, but the
role of the individual Smad proteins in the proper function of the ovary is just beginning to be
understood for example through the use of Smad knockout models. Although most of the different
Smad knockouts are embryonic lethal, it is known, however, that in Smad1 and Smad5 knockout
mice primordial germ cell development is impaired and that Smad3 deficient mice harbouring a
deletion in exon 8 exhibit impaired folliculogenesis and reduced fertility. In this minireview we
discuss the role of Smad structure and function in the ovarian context.
Background
The main function of the female ovary is the production
of the mature oocyte for fertilization to allow subsequent
generation of healthy progeny. The ovary also has an
endocrine function which is essential for the sexual matu-
ration and reproductive ability of the female. The estab-
lishment of the germ line that gives rise to the oogonia
and further the oocytes is therefore of fundamental
importance for animal reproduction. Several growth fac-
tors belonging to the transforming growth factor β (TGF-
β) superfamily together with their receptors and intracel-
lular signalling molecules, the Smads, have been shown to
be indispensable for the critical ovarian functions such as
oocyte formation and development as well as ovarian fol-
liculogenesis [1-3]. The temporal and spatial regulation of
these signalling cascade molecules determines the respon-
siveness of the ovarian cell types to each stimulus during
the course of folliculogenesis. Consequently, defects at
either the growth factor, receptor or intracellular effector
level may abrogate proper signalling and lead to adverse
effects in fertility as is shown by extensive knockout stud-
ies in mice (for reference see [1]). In this minireview, we
focus on the role of the different Smads, the downstream
effectors of TGF-β superfamily ligands, in the ovarian org-
anogenesis and folliculogenesis.
Proteins belonging to the Smad family were first identi-
fied in the fruit fly Drosophila melanogaster in the mid
1990s by Sekelsky et al. who found that an intracellular
protein named Mad mediates the signalling of decapenta-
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sponding to mammalian bone morphogenetic protein 2
or 4 (BMP-2/4) [4]. The discovery of orthologous proteins
in Caenorhabditis elegans (Sma-proteins) as well as in ver-
tebrates soon followed, and the newly found protein fam-
ily was termed Smad [5]. Today, eight different members
of the Smad family have been identified in mammals and
an additional Smad4 identified in Xenopus laevis was
termed Smad4β [6]. Based on their function, the Smads
are classified as receptor-activated (R-) Smads (Smad1, -2,
-3, -5 and -8), common-partner (Co-) Smads (Smad4,
Xenopus Smad4α and Smad4β) or inhibitory (I-) Smads
(Smad6 and -7). They function as intracellular transcrip-
tion factors that mediate the signalling of the TGF-β super-
family which comprises now of more than 40 members
including three isoforms of TGF-β, activins, inhibins,
growth differentiation factors (GDFs) and bone morpho-
genetic proteins. All ligands in this protein family share
common sequence elements and structural motifs. They
are multifunctional regulators of cell proliferation, differ-
entiation, migration and apoptosis, promoting extracellu-
lar matrix production, tissue homeostasis and
embryogenesis. The TGFβ superfamily ligands are biolog-
ically active as homo- or heterodimers. As the ligand binds
to the transmembrane type I and type II serine/threonine
kinase receptors on the cell surface both receptor types
dimerize forming a tetrameric signalling complex. Five
type II Ser/Thr kinase receptors, and seven type I receptors
have been identified so far. The type II receptor is consid-
ered to be constitutively active and it activates the type I
receptor at its juxtamembrane GS-domain through phos-
phorylation. Furthermore, betaglycan and endoglin func-
tion as accessory receptors ("type III receptors") and
modulate TGF-β activity. Depending on the combination
of type I and type II receptors, different R-Smads are acti-
vated through phosphorylation by the type I receptor
upon ligand binding. R-Smad2 and -3 are phosphorylated
by activated TGF-β/activin type I receptors, and Smad1, -5
and -8 act downstream of BMP type I receptors. Activated
R-Smads form oligomeric complexes with Co-Smad4 and
translocate into the nucleus where they regulate target
gene expression via interaction with a multitude of other
transcription factors, co-activators and co-repressors.
Inhibitory Smads block TGF-β superfamily signalling by
binding to the type I receptors (Smad7) or by competing
with activated R-Smad1 for binding to Co-Smad4
(Smad6). Smad7 can inhibit the activation of both the
TGF-β/activin and BMP pathway R-Smads, whereas
Smad6 is an inhibitor of BMP signalling [7-9].
Previously it was thought that the oocyte had a passive
role in the events of folliculogenesis and the somatic gran-
ulosa cells were the main effectors. However, it is now
well acknowledged that a bi-directional communication
axis exists between the oocyte and its surrounding somatic
cells; the oocyte regulates the differentiation and prolifer-
ation of the surrounding granulosa cells which in return
secrete factors that modulate the growth of the oocyte
itself [10,11]. Consequently, a complex interplay of regu-
latory factors governs the development of both cell types.
In addition to pituitary endocrine hormones LH and FSH,
a number of paracrine and autocrine factors, including
several TGF-β superfamily members expressed by different
ovarian cell types, contribute to the regulation of follicu-
logenesis. Gene expression studies have revealed in partic-
ular the BMP subfamily and their antagonists, as well as
their transmembrane receptors and intracellular signal-
ling molecules, play an important role throughout embry-
onic development and organogenesis. Concomitantly,
these growth factors exhibit coordinated spatial and tem-
poral expression patterns in fundamental cell types
throughout the reproductive system and during game-
togenesis. Gene knockout studies with mice have shown
that certain BMPs and their downstream Smad effectors
are required for germ line establishment. Both Smad1 and
Smad5 knockout mice, although they die in the uterus
during embryogenesis, show defective primordial germ
cell (PGC) formation like BMP-4 and -8b deficient mouse
embryos that survive gastrulation [3,12,13]. During ovar-
ian folliculogenesis, Smad2 and Smad3 are expressed in a
stage specific manner in the rat, possibly allowing differ-
ent effects of the TGF-β superfamily ligands that use the
same signalling pathways [14]. In the first part of this
minireview we describe the structure and function of the
Smad proteins as intracellular signalling molecules and
present a multi-species alignment of the Smads that high-
lights the structural relatedness of the various Smad sub-
groups. In the second part we describe the Smad signalling
pathways utilized by the different TGF-β superfamily lig-
ands within the ovary and discuss the different ovarian
phenotypes with defective Smad signalling.
Smad structure
The Smads contain two main domains that are conserved
within the protein family, an N-terminal Mad homology
1 (MH1) domain and a MH2 domain in their C-terminus,
that are connected by a non-conserved proline-rich linker
region (Figure 1). The MH1 domain is highly conserved
between the R-Smads and Co-Smads whereas the N-termi-
nal region of the I-Smads shares only weak sequence sim-
ilarity with the MH1 domain. In contrast, the MH2
domain is highly conserved among all Smads. The MH1
domain of the R-Smads and Co-Smads binds with low
affinity to DNA recognizing specific sequences termed
Smad binding elements (SBE) in the promoters of their
target genes. However, the full length Smad2 lacks DNA-
binding ability due to an insertion of the exon 3 coding
for a 30-amino acid peptide in the MH1 domain [15].
Directed deletion of the exon 3 from full length Smad2
restores DNA binding ability allowing the expression ofPage 2 of 13
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ligands [16]. The MH1 domain confers the ability to inter-
act with other transcription factors and contains a nuclear
localization sequence (NLS) and physically interacts with
the MH2 domain exerting an autoinhibitory effect against
Smad activation [17].
The linker region connecting the MH1 and MH2 domains
is less conserved between the different Smads but contains
several important regulatory peptide motifs, including
potential phosphorylation sites for mitogen activated pro-
tein kinases (MAPKs). In addition, the linker region con-
tains phosphorylation sites for the Erk-family MAP
kinases [18], the Ca2+/calmodulin-dependent protein
kinase II (CamKII) [19] and protein kinase C (PKC) [20].
A proline-tyrosine (PY) motif present in most R-Smads
and I-Smads enables Smad interaction with the WW
domains of the E3 ubiquitin ligases Smurf1 and Smurf2
(Smad ubiquitination-related factors) and SCF/Roc1
[21,22], and ubiquitin-mediated proteasomal degrada-
tion. Smad4 linker region also includes a nuclear export
signal (NES) [23] and a Smad4 activation domain (SAD)
that is required in transcriptional complexes mediating
the activation of Smad-dependent target genes [24].
The MH2 domain is a multifunctional region that medi-
ates type I receptor recognition through the L3 loop, tran-
scriptional activation and R-Smad oligomerization with
Smad4. It is also essential for cytoplasmic anchoring of
the R-Smads as well as the interaction with Smad binding
proteins and transcription factors. R-Smads are activated
through phosphorylation of two serine residues at their C-
terminal SSXS motif by the activated type I receptor at the
inner leaflet of the cell membrane, whereas the I-Smads
and the Co-Smads can not be phosphorylated C-termi-
nally.
Analysis of the Smad protein sequences based on a com-
bined cross-paralogue/cross-orthologue multiple
sequence alignment (GoCore 5.0, Jeffery et al., manu-
script in preparation; see references for the website
address) highlights the structural relatedness of the vari-
ous Smad subgroups (Additional file 1). The BRE pathway
Smads (1/5/8) and the TGF-β/activin pathway Smads (2/
3) form distinct groups. This grouping is particularly evi-
dent in the linker region, although this region otherwise
exhibits a relatively low degree of homology across the R-
Smad proteins. The grouping can also be observed in
localized sites of the MH1 and MH2 domains.
Smad signal transduction
Inactive R-Smads reside predominantly as monomers in
the cytoplasm whereas the I-Smads localize to the cell
nucleus [25,26]. Smad4 constitutively shuttles between
cytoplasm and nucleus and its cytoplasmic localization in
unstimulated cells is due to active nuclear export [23,27].
Cytoskeletal proteins also play a part in the localization
and signalling of Smads. Unphosphorylated Smad2 and
Smad3 bind microtubule filaments, and TGF-β treatment
induces dissociation of these complexes [28]. Smads also
interact with filamin, a scaffold for intracellular signalling
proteins that crosslinks actin [29]. Upon ligand binding,
the R-Smads are activated through C-terminal phosphor-
ylation by the activated type I receptor at the inner leaflet
of the cell membrane. A ligand can induce different sig-
nalling pathways depending on the composition of the
receptor complex. Substrate specificity is determined by
the L45 loop in the intracellular domain of the type I
receptors and primarily by the L3 loop in the MH2
domain in the R-Smads [30,31]. Upon ligand binding, the
activated type I and II receptors may be internalized via
clathrin coated pits into early endosomes that contain a
protein named SARA (Smad anchor for receptor activa-
tion) [32]. SARA is a FYVE domain containing scaffolding
protein that interacts with the MH2 domain of inactive
Smad2 and Smad3 targeting them to early endosomes
and aiding in the recruitment of Smads to their receptors,
thus promoting Smad phosphorylation and TGF-β signal-
ling [33]. A recent discovery by Lin et al. reveals that a
cytoplasmic protein named PML (promyelocytic leukae-
A schematic structure of the SmadsFigur  1
A schematic structure of the Smads. The N-terminal MH1 
domain (light blue) and C-terminal MH2 domain (dark blue) 
are conserved among Smads. The non-conserved regions 
including the linker are shown in white. The two Serine (S) 
residues at the C-terminus of R-Smads that are phosphor-
ylated by the type I receptor are marked with asterisks. MH 
Mad homology domain; PY, the proline-tyrosine (PPXY) 
motif identified by the E3 ligases Smurf1 and Smurf2; SAD, 
Smad4 activation domain.
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Smad3 and SARA and is required for the association of
Smad2 and -3 with SARA [34]. PML expression is induced
by TGF-β and it is required for the accumulation of SARA
and the TGF-β receptors in the early endosomes. Several
other accessory/scaffolding proteins like SARA have been
discovered for the TGF-β pathway R-Smads e.g. axin and
disabled2 (Dab2) [35,36], but no accessory proteins have
yet been discovered for the BMP-pathway Smads.
Recently, Runyan et al. have shown that endocytosis of the
receptor complex is required for proper nuclear transloca-
tion of activated Smads in human kidney mesangial cells,
and that internalization enhances the dissociation of
phosphorylated Smad2 from the TGF-β-receptor-SARA
complex [37]. Internalization of the receptor complex
through an alternate route, a lipid raft/caveolar dependent
pathway, leads to the degradation of the receptor complex
and thus regulates Smad activation and receptor turnover
[32]. Following phosphorylation, Smads can form oli-
gomers at different stochiometries; heterotrimers with
two R-Smads and one Smad4 (Smad3) [38] or heterodim-
ers consisting of an R-Smad (Smad2) and a Co-Smad [39].
Activated Smads accumulate into the nucleus where they
control target gene expression in a cell type specific man-
ner through interactions with other transcription factors,
corepressors and coactivators. Diverse ligand responses in
different cell types are a result of different Smad-interact-
ing transcription factors and of cooperation with other
signalling pathways.
Modulation of Smad activation
TGF-β superfamily signalling is modulated at multiple
levels. Extracellular ligand trapping molecules or antago-
nists, including gremlin, noggin, chordin (all members of
DAN/Cerberus protein family) and follistatin, can block
ligand binding to the receptors. Another antagonist is the
naturally occurring pseudoreceptor BAMBI (BMP and
Activin membrane bound inhibitor) which extracellular-
ily resembles a type I receptor but lacks the cytosolic
kinase domain. BAMBI can form stable associations with
various TGF-β family type I receptors thus blocking BMP,
activin and TGF-β signalling [40]. Receptor internaliza-
tion provides another point of modulation of the signal
transduction pathway as mentioned above. Also within
the cell, alterations in Smad protein levels can profoundly
affect signalling. The basal levels of Smad proteins are reg-
ulated post-translationally through a ubiquitin-mediated
proteasomal degradation pathway [41,42]. Both the size
of the Smad pool in unstimulated cells and the levels of
activated Smads are thus regulated. The E3 ligases, Smurf1
and -2, as well as SCF/Roc1, antagonize TGF-β family sig-
nalling through interaction with R-Smads, targeting them
for degradation and terminating Smad-mediated signal-
ling [22,41,43]. Therefore, Smurf-mediated degradation
regulates R-Smad levels and the sensitivity of cells to
incoming signals.
In contrast to R-Smad expression, expression of the inhib-
itory Smad6 or Smad7 is regulated by extracellular signals.
Induction of Smad6 and Smad7 expression by BMP and
TGF-β, respectively, represents an auto-inhibitory feed-
back mechanism for ligand-induced signalling [8,44].
Recruitment of a complex of Smad7 with either Smurf1 or
Smurf2 to the type I TGF-β receptors at the cell membrane
results in receptor ubiquitination and degradation. Inter-
nalization of the receptor complex bound to Smad7 via
lipid raft caveolin-positive compartments promotes poly-
ubiquitination and results in accelerated receptor turno-
ver [32]. Activation of the epidermal growth factor (EGF)
receptor, and possibly other tyrosine kinase receptors,
interferon-γ signalling through STAT (signal transducer
and activator of transcription) proteins, and activation of
NF-κB by tumour-necrosis factor-α, also induce Smad7
expression [45]. In addition to the Smurfs, inhibitory
Smad6 and Smad7 also modulate the Smad-mediated sig-
nalling. Smad7 inhibits both TGF-β and BMP pathway
Smad activation through interaction with the type I recep-
tor, whereas Smad6 blocks only BMP pathway Smads by
competing with the activated R-Smads for heteromeric
complex formation with Co-Smad4 [25]. Co-repressors c-
Ski and SnoN are two highly conserved members of the
Ski family of proto-oncoproteins and they can antagonize
TGF-β signalling through direct interactions with Smad4
and the R-Smads inhibiting transcription of target genes
[46].
Members of the MAP kinase family are frequently
involved in TGF-β/Smad signalling and nuclear accumu-
lation of activated Smads can be modulated by Ras acti-
vated Erk kinases. Epidermal growth factor (EGF),
hepatocyte growth factor and oncogenic Ras stimulate Erk
kinases, which in turn phosphorylate Smad proteins. Erk
phosphorylates serine residues in the linker regions of
Smad1 [18], Smad2 and Smad3 [47]. Phosphorylation of
Smads can also result from the activation of MAPK/Erk
kinase kinase 1 (MEKK1), which acts downstream from
Ras and upstream from the growth factor-induced Erk
MAPK and stress-activated SAPK/JNK pathways [48].
Phosphorylation of Smads in the MAP kinase sites at the
linker region attenuates ligand-induced nuclear transloca-
tion and alters Smad-dependent transcription. Dephos-
phorylation of the Smads by as yet unidentified
phosphatases is another mechanism for the termination
of Smad signalling. Activation of Ca2+/calmodulin-
dependent protein kinase II (CamKII) also results in
Smad2, Smad3 and Smad4 phosphorylation inhibiting
TGF-β-induced nuclear import and transcriptional activity
of Smad2, and affecting Smad heteromerization [19]. Pro-
tein kinase C (PKC) activity abrogates DNA binding ofPage 4 of 13
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pendently of TGF-β stimulation at Ser249 [49], whereas it
is unknown whether Smad6 is modulated by phosphor-
ylation. Smad7 phosphorylation does not affect TGF-β
signalling but rather the TGF-β independent effect of
Smad7 on transcriptional regulation [49]. In conclusion,
phosphorylation of the Smads not only causes their acti-
vation but also modulates their activity and provides a
mechanism for integration of the Smad pathway with
other signalling pathways that can modulate TGF-β super-
family signalling.
TGF-β superfamily ligands in ovarian organogenesis and 
folliculogenesis
The establishment of the germ line is of fundamental
importance to animal reproduction. In mice, the extraem-
bryonic ectoderm induces germ cell determination [50].
During early embryonic development in mice, uncommit-
ted epiblast cells in the extra-embryonic mesoderm invo-
lute through the primitive streak to the yolk sac endoderm
and become committed as primordial germ cells (PGCs).
These cells proliferate and migrate via the yolk sac into the
hind gut endoderm and dorsal mesentery, and finally to
the genital ridges during gastrulation. Upon reaching their
destination, PGCs lose their motility, become encapsu-
lated by the primary sex cords and differentiate depending
on the sex chromosome set up into oogonia or spermato-
gonia. The cortical sex cords give rise to the female ovaries,
whereas the medulla slowly deteriorates [51]. The process
of gametogenesis starts as the PGCs leave the dorsal
mesentery and continues as they enter and colonize the
genital ridges to establish the prospective gonad. The role
of the TGF-β superfamily ligands in ovarian organogene-
sis as well as folliculogenesis has been studied extensively
in animals. In particular, the BMPs together with their
antagonists have been shown to be prominent through-
out embryonic development and organogenesis. Gene
ablation studies in mice have identified BMP4, -8b and -2
as regulators of primordial germ cell (PGC) formation
from epiblast cells, BMP-2 deriving from the embryonic
endoderm and BMP-4 and -8b from the extra-embryonal
ectoderm [3]. Targeted mutations of either BMP-4 or
BMP-8b lead to severe defects in PGC formation in the
embryos that survive gastrulation [3]. Also, altered germ
cell migration in the absence of TGF-β signalling via ALK-
5 has been reported [52].
Within the established ovary, the progress of folliculogen-
esis is in part regulated by peripheral endocrine factors,
the pituitary gonadotropins FSH and LH as well as growth
hormone (GH) and prolactin in some species. In addi-
tion, intraovarian factors, such as steroids, cytokines and
other growth factors act in a paracrine/autocrine manner
and co-ordinately contribute to the processes of recruit-
ment, development, atresia, selection and ovulation of
follicles [53]. The growth of the follicle is considered
gonadotropin-independent to the small antral stage and
during these early phases folliculogenesis appears to be
driven by the local autocrine and paracrine signals from
the oocyte and the surrounding somatic cells. A complex
bi-directional communication between the oocyte and
granulosa cells as well as between the granulosa and the-
cal cells drives the progression of follicular development
through successive stages [54]. Various TGF-β superfamily
ligands expressed by the different ovarian cell types are
important in this interaction and their expression is regu-
lated in a developmental-stage related manner. Among
the local factors at least activins, inhibins, TGF-β s, BMP-
6, GDF-9 and its homologue GDF-9B (also known as
BMP-15) as well as anti-Müllerian hormone (AMH, also
known as Müllerian inhibiting substance, MIS) are impli-
cated in having a role during the development of follicles
(for review, see [51]). The developing oocyte has been
shown to express GDF-9, GDF-9B, BMP-6 and TGF-β 2,
although the TGF-β protein may not be secreted [55-59].
Granulosa cells produce activins, inhibins, TGF-β s, BMP-
2, BMP-3 and BMP-6 as well as AMH at different stages of
folliculogenesis, while the theca cells have been reported
to produce all the isoforms of TGF-β, BMP-3b, BMP-4 and
BMP-7 [60,61]. TGF-β s, activins and GDF-9 signal
through the Smad2/3 pathway whereas GDF-9B, BMP-2, -
4, -6 and -7 utilize the Smad1/5/8 pathway (see Table 1).
Table 1 summarizes the different superfamily ligands
expressed by the oocyte, granulosa cells and thecal cells as
well as their receptors and the Smad pathways they acti-
vate when known.
For appropriate signalling, an intact signalling cascade
from ligands and receptors to intracellular effectors and
accessory proteins has to be present and functional. The
temporal and spatial regulation of these signalling cas-
cade molecules determines the responsiveness of the cell
type to each stimulus, and the direction of signalling
within the follicle is dependent on cellular distribution of
the whole signalling pathway. Reproductive defects can be
found in knockout mice at all levels of the signalling cas-
cade; at the ligand level activin β B, inhibin α, GDF-9,
GDF-9B and AMH are known to cause fertility defects, at
the receptor level, ALK6 (also known as BMP type IB
receptor) and AMH type II receptor (AMHRII) affect
female fertility, and finally at the intracellular effector
level, Smad3 knockout mice exhibit reduced fertility
[1,2,62]. Ingman et al. very recently reported that TGF-β 1
null mice show severely impaired reproductive capacity
and almost complete infertility [63]. In the following sec-
tion we discuss the main TGF-β superfamily ligands
expressed by the different follicle cell types; the oocyte,
granulosa and thecal cells as well as their target cells and
signalling pathways.Page 5 of 13
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In most mammalian species, both GDF-9 and GDF-9B
mRNA and protein expression begin at the primary folli-
cle stage and continue throughout the development of the
maturing follicle [55,56,64]. Depending on the species,
both GDF-9 and GDF-9B are indispensable for normal
progression of ovarian folliculogenesis as shown by the
mouse and sheep animal models [65-67]. GDF-9 deficient
mice display arrested follicular development at the pri-
mary follicle stage, the theca cell layer is absent and in
addition their oocyte development is compromised.
Therefore, the homozygous female mice are infertile while
heterozygous females and male mice are not affected [65].
A naturally occurring mutation in the GDF-9 gene has
been discovered recently in sheep that causes sterility in
homozygous ewes due to abnormal follicle development,
but surprisingly, increased ovulation rate and fertility in
heterozygotes [67].
In contrast to the mouse GDF-9 knockout, female mice
completely lacking GDF-9B are fertile but exhibit reduced
fertility due to defects in the ovulation process and the
ability of oocytes to develop into normal embryos,
whereas heterozygous females exhibit normal fertility
[68]. In sheep, four different mutations in the GDF-9B
gene have been identified that affect fertility and ovula-
tion rate, introducing premature stop codons (Belclare
and Cambridge sheep FecXG or Hanna mutation FecXH) or
non-conservative amino acid substitutions within the
mature protein (Inverdale FecXI or Belclare FecXB)
(reviewed in [69]). All these mutations cause an arrest in
folliculogenesis at the primary follicle stage in
homozygous animals similar to the phenotype of the
GDF-9 knockout mouse. In contrast, heterozygous ewes
exhibit increased ovulation rates and fertility. The reason
for these difference in phenotypes between mice and
sheep is not fully understood but it has been suggested,
however, that the differences may derive from the differ-
ent ovulatory nature of these species, the sheep being a
low ovulation rate species and the mice a poly-ovulatory
species, or the different relative importance of these
growth factors in sheep and mice [68,70].
The biological functions of the oocyte secreted GDF-9
have been studied extensively over the past five years, and
an essential role for GDF-9 in the early stages of folliculo-
genesis as well as during ovulation is emerging. Recom-
binant GDF-9 functions as a granulosa cell mitogen and
has been shown to modulate granulosa cell steroidogene-
sis. In addition, it has been shown to stimulate the growth
of preantral rat follicles and the proliferation of rat and
mouse granulosa cells [71-74] as well as to induce the
cumulus cell phenotype during ovulation [72]. Only a few
target genes for GDF-9 have been identified so far. GDF-9
has been shown to induce granulosa cell hyalurononan
synthase 2 (Has2), cyclo-oxygenase 2 (Cox2), and ster-
oidogenic acute regulatory protein (StAR) mRNA expres-
sion and to suppress the protease urokinase plasminogen
activator (uPa) and luteinizing hormone receptor (LHR)
as detected with semi-quantitative RT-PCR [72,75]. With
a microarray approach, Varani et al. found that GDF-9
induces pentraxin 3 expression in mural granulosa cells
from preovulatory mouse follicles [76] and recently, Pan-
gas et al. identified gremlin, a BMP antagonist, as a gene
regulated by GDF-9 in mouse granulosa cells from large
antral follicles [77]. GDF-9 may also modulate theca cell
function as it is known to stimulate the expression of
CYP17, a theca cell marker [78], and androgen biosynthe-
sis in rat theca-interstitial cells [79] as well as to inhibit
3'5'-adenosine monophosphate-stimulated steroidogene-
sis in human theca cells [80].
Few targets for GDF-9B have been identified, however, it
is known to suppress FSH receptor mRNA expression [81],
Table 1: Signalling pathways of TGF-β superfamily ligands expressed in the ovary.
Ligand Expressed by Type II receptor Type I receptor Smads References
GDF-9 oocyte BMPRII ALK5 Smad2/3 [86-88]
GDF-9B/BMP-15 oocyte BMPRII ALK6 Smad1/5/8 [91]
BMP-6 oocyte, granulosa cell BMPRII/ActRIIA/B ALK2/ALK3/ALK6 Smad1/5/8 [94-96]
TGF-β 1, -2, -3 granulosa and theca 
cell
TβRII ALK5 Smad2/3 [132, 133]
Activin A/B granulosa cell ActRIIB ALK4 Smad2/3 [134, 135]
Inhibin α granulosa cell ActRIIA/ActRIIB ? ? [136]
BMP-2 granulosa cell BMPRII/ActRIIA ALK3/ALK6 Smad1/5/8 [137, 138]
BMP-3 granulosa cell ActRIIB ? ? [106]
AMH/MIS granulosa cell AMHRII ALK2/ALK3/ALK6 Smad1/5/8 [111, 113-115]
BMP-3b theca cell ? ? ? [139]
BMP-4 theca cell BMPRII/ActRIIA ALK3/ALK6 Smad1/5/8 [137, 138, 140]
BMP-7 theca cell BMPRII/ActRIIA ALK2/ALK3/ALK6 Smad1/5/8 [140, 141]Page 6 of 13
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[82] and to simultaneously promote expression of anti-
apoptotic Bcl-2 and suppress pro-apoptotic Bax [83].
Recombinant GDF-9B functions as a granulosa and cumu-
lus cell growth factor by actively preventing cell death and
promoting DNA synthesis and proliferation in vitro
[81,83]. In the light of recent data it is becoming clear that
GDF-9 and GDF-9B can co-operate to regulate granulosa
cell functions e.g. proliferation and gonadotropin-
induced differentiation [84,85].
GDF-9 has been shown to mediate its signal through cell
surface receptors BMPRII, that normally functions as a
BMP type II receptor, and ALK5, the type I receptor of TGF-
β, and activates Smad2/3 pathway [86-90]. The GDF-9
receptor combination is interesting since this is the first
reported physical interaction between ALK5 and a BMP
type II receptor. GDF-9B interacts with BMPRII and has
also been shown to interact with ALK6 (or BMP receptor
type IB) and causes the activation of Smad1/5/8 pathway
[91]. The receptor complex binding a GDF-9-GDF-9B het-
erodimer has not been reported yet, but it could be pre-
dicted to consist of two BMPRII molecules in complex
with one ALK5 and one ALK6 molecule. Interestingly, a
naturally occurring point mutation was found in sheep in
the gene coding for ALK6 (Booroola gene FecB), the type
I receptor for e.g. GDF-9B, which causes increased ovula-
tion rates in heterozygous sheep compared to wild type
sheep, and even higher ovulation rates in homozygotes
[92]. Although GDF-9B, BMP-2, -4, -6 and -7 are
expressed in the mammalian ovary and can signal
through ALK6, it is not known to what degree each of
these is involved in the Booroola phenotype. However,
based on the similarity of the phenotype with the hetero-
zygous Inverdale ewe with a point mutation in the GDF-
9B protein coding gene, the involvement of altered BMP-
15 signalling is strongly suspected [92], GDF-9B showing
the highest affinity to ALK6 of the type I receptors [91].
The follicles of these Booroola ewes mature and ovulate at
smaller sizes with fewer granulosa cells than in wild-type
ewes. The ALK6 knockout mouse phenotype differs from
the Booroola sheep phenotype. The knockout mice
appear to have normal ovarian follicular development
and ovulation rates, but display reduced fertility which
may be caused by the failure of normal cumulus expan-
sion [2].
BMP-6 is the third TGF-β superfamily growth factor
secreted by the oocyte from the primary stage onwards
[58] but it lacks the mitogenic activity of GDF-9 and GDF-
9B (Gilchrist et al., 2005 submitted) [93]. BMP-6 modu-
lates granulosa cell steroidogenesis by inhibiting FSH-
induced progesterone synthesis, but has no effect on estra-
diol production. BMP-6 suppresses the FSH action at the
level of adenylate cyclase downstream of the FSH receptor
in contrast to GDF-9B which suppresses FSH receptor
expression [81,93]. The preference of cell surface receptors
for BMP-6 in the ovary has not been determined yet but
BMPRII, ActRII as well as ActRIIB have been implicated as
type II receptors for BMP-6 [94,95] and all BMP ALKs
(ALK2, -3 and -6) have been identified as potential BMP-
6 type I receptors, with ALK6 having the strongest binding
affinity [95,96]. BMP-6 can activate the Smad1/5/8 path-
way in a human granulosa tumour cell line [91].
The granulosa cells
Activins and inhibins were first discovered as gonadal pro-
teins that regulate pituitary FSH secretion [97]. Three
types of activin are produced in the ovary by the granulosa
cells, each consisting of a dimer of two related subunits β
A and β B i.e. homodimeric activin A (β Aβ A) and activin
B (β Bβ B), and a heterodimeric activin AB (β Aβ B). Two
types of inhibin are also expressed by granulosa cells.
Inhibins consist of one inhibin α-subunit and one activin
subunit forming either inhibin A (α-β A) or inhibin B (α-
β B). Activin produced by the secretory gonadotrophs in
the anterior pituitary stimulates FSH production in a para-
crine manner, and within the ovary activin promotes
granulosa cell proliferation [98] as well as potentiates FSH
actions by increasing FSH receptor expression [99].
Activin also modulates granulosa and theca cell steroido-
genesis. Activins are produced by the granulosa cells and
the expression pattern of the different activin subunit
mRNAs changes during folliculogenesis.
Inhibins are also produced by the granulosa cells, and
they act as endocrine hormones that are released into the
circulation to suppress pituitary FSH production. Locally,
inhibins also act as potent regulators of activin signalling.
Inhibins compete with activin signalling by blocking
activin binding to type II activin receptors. β-glycan, an
inhibin co-receptor, facilitates inhibin binding to the
activin type II receptor [100]. Follistatin (FS) is yet
another granulosa cell produced inhibitor of activin func-
tion which also regulates the actions several BMPs, includ-
ing GDF-9B/BMP-15 [83]. Follistatin antagonises activin
through forming biologically inactive complexes. Activin
subunits bind ActRIIB and ALK4, and activate the Smad2/
3 pathway whereas the inhibin α-subunit binds to ActRIIA
or ActRIIB. Cripto, a prototypic member of the epidermal
growth factor-Cripto protein family, antagonises activin
signalling by binding to the activin type II receptor and
blocking ALK4 recruitment [101].
Also BMP-2, BMP-3 and BMP-6 are expressed by the gran-
ulosa cells [102,103]. Recombinant BMP-2 has been
shown to amplify FSH-induced estradiol and inhibin A
production in sheep granulosa cells [104] and stimulate
inhibin β B subunit mRNA expression as well as inhibin B
protein production in cultured human granulosa lutealPage 7 of 13
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4:21 http://www.rbej.com/content/4/1/21cells [105]. BMP-2 can signal through either BMPRII or
ActRIIA and ALK3 and -6 activating the Smad1/5/8 path-
way. BMP-3 mRNA has been shown to be expressed in
human granulosa luteal cells but the biological function
of BMP-3 in the ovary is still unclear. However, it was
reported that the expression level of BMP-3 is regulated by
human chorionic gonadotropin (hCG) [103]. Recently, it
was discovered that BMP-3 binds ActRIIB and functions as
a novel inhibitor for both activin and BMP-4 signalling in
Xenopus embryos [106]. BMP-6 expression in granulosa
cells is first detected at the early secondary stage in rat fol-
licles and it is rapidly lost at the time of dominant follicle
selection suggesting that inhibition of BMP-6 gene activity
may be required for the formation of the dominant folli-
cle. BMP-6 is again highly expressed in atretic follicles sup-
porting this hypothesis [102].
AMH is expressed by the Sertoli cells in the testis and gran-
ulosa cells in the ovary [107]. In the male AMH causes the
regression of Müllerian ducts that in the female differenti-
ate into the oviducts, the uterus and the upper part of the
vagina. In the granulosa cells AMH is first expressed post-
natally in primordial follicles recruited to growth and con-
tinues to be expressed until the growing follicles are
selected for dominance by the action of FSH. AMH defi-
cient mice are fertile but their pool of primordial follicles
is depleted earlier than wild type mice [108]. AMH has
been shown to inhibit the initiation of primordial follicle
growth in the neonatal mouse ovaries as well as inhibit
the stimulatory effect of FSH on the growth of preantral
and small antral follicles [107]. Instead, in the rat, AMH
promotes preantral follicle growth in the presence of FSH
but not preantral follicle cell differentiation and apoptosis
[109] and in human, it was recently found that AMH
induces growth of primordial follicles from ovarian corti-
cal tissue [110]. AMH binds to the AMH type II receptor
[111] and causes the activation of Smad1/5/8 in a granu-
losa tumour cell line [112], but the type I receptor has yet
to be conclusively confirmed (ALK2,-3 and -6 are impli-
cated) [113-115].
The theca cells
A theca cell layer forms to surround the developing follicle
outside the basal lamina at the primary/secondary transi-
tion. Theca cells from rat follicles have been shown to pro-
duce BMP-3b, BMP-4 and BMP-7, as well as all the
isoforms of TGF-β [102,116,117]. Recombinant BMP-4
and -7 have been found to modulate FSH signalling by
promoting FSH induced estradiol production and inhibit-
ing progesterone biosynthesis [116]. Granulosa cells in
growing follicles produce estradiol but no progesterone in
vivo in response to FSH stimulation until the periovula-
tory period, whereas in vitro cultured granulosa cells pro-
duce progesterone as well as estradiol in response to FSH
stimulation. Therefore, it has been suggested that the bio-
logical function of theca cell derived BMPs might be to
function as selective inhibitors of progesterone synthesis
(luteinization inhibitors) as neither BMP-4 or BMP-7
affect granulosa cell steroidogenesis in the absence of FSH
in the rat [116]. Both BMP-4 and -7 bind to the BMPRII/
ActRIIA receptors and ALK3 and -6 which are predomi-
nantly expressed in granulosa cells [116], BMP-7 may also
signal through ALK2 [118]. Both activate the Smad1/5/8
pathway in their target cells.
In conclusion, the oocyte secreted factors GDF-9, GDF-9B
and BMP-6 can activate either Smad2/3 or Smad1/5/8
pathways in the granulosa cells and modulate their differ-
entiation and proliferation. However, Smad2/3 signalling
is by far the predominate pathway used by oocyte secreted
factors to promote granulosa and cumulus cell growth
and cumulus cell expansion (Gilchrist et al., submitted).
It is not clear, however, to what extent Smad mediated sig-
nalling is involved in the oocyte maturation process dur-
ing folliculogenesis or whether the oocyte secreted factors
have autocrine effects on the oocyte itself. The human
oocyte shows immunostaining for Smad2 and Smad4 at
primordial and primary stages of folliculogenesis, having
therefore the capacity to respond to TGF-β-like ligands but
little is known of the significance of the Smad1/5/8 path-
way in the oocyte development [119]. The granulosa cell
expressed ligands may act locally in a paracrine or auto-
crine fashion affecting the granulosa cells themselves or
the thecal cells and possibly even the oocyte, or they may
have systemic effects acting on for example the pituitary
gonadotropin expression of activins and inhibins.
What do transgenic mouse models tell about Smad 
signalling in the ovary?
The downstream effectors of the TGF-β superfamily lig-
ands, the Smads, are expressed ubiquitously throughout
development in practically all adult tissues and are also
essential for normal embryonic development. Although
the targeted disruption of individual receptor-regulated
Smad genes in mice (Smad1, -2, -4, or -5) results in the
death of homozygous embryos, the knockout models
have nevertheless revealed different roles for the Smads at
different stages of embryogenesis. The Smad1 knockout
mouse shows impaired allantois formation and also
markedly reduced primordial germ cell (PGC) formation
[12,120], whereas Smad2 deleted mutant mice have
defects in mesoderm induction, left-right patterning and
craniofacial development [121,122]. Interestingly, Dunn
et al., recently showed that deleting the exon 3 of the full
length Smad2 restores its DNA binding ability, and that
homozygous mice exclusively expressing the short iso-
form Smad2(∆ exon3) are viable and fertile [16]. Conse-
quently, the short isoform of Smad2, or the replacement
of the coding sequence of full length Smad2 with closely
related Smad3, can activate all essential target genesPage 8 of 13
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suppressor Smad4 is required during gastrulation and
later in the anterior development of the mouse embryo as
shown by the Smad4 knockout mouse [123]. Smad5
knockout mice have multiple embryonic and extra-
embryonic defects [124]. Interestingly, homozygous
Smad5 knockout mice that die at midgestation also show
a greatly reduced number or total loss of PGCs [13], sim-
ilar to what happens in the BMP4 and -8b knockout mice
[3].
Two different Smad3 knockout mice have been generated
with disruptions in either the exon 2 or exon 8. In contrast
to the other R-Smad knockout mice, the Smad3 deficient
mouse is viable displaying various defects, such as acceler-
ated wound healing (KO in exon 8) [125], impaired
immune function and diminished responsiveness of T
cells to TGF-β (KO in exon 8) [126] and a predisposition
to colorectal adenocarcinomas (KO in exon 2) [127]. Zhu
et al. reported that the Smad3 null mice with deletion of
exon 2 are fertile but produced smaller litters [127]. In
contrast, the ovarian function in the Smad3 null mice har-
bouring a deletion in the exon 8 has been reported to be
abnormal. The mice exhibit reduced fertility and circulat-
ing estrogen levels due to impaired folliculogenesis, and
also underdeveloped mammary glands compared to
female wild type mice [62,128]. The primordial pool of
follicles at birth is not affected by the mutation and the
ovaries appear similar to the wild type mouse but later in
postnatal life the ovaries of Smad3 deficient mice have
higher numbers of primordial follicles and fewer large
preantral and antral follicles than wild type mice, suggest-
ing that the absence of Smad3 may delay follicular matu-
ration [62,126]. More detailed study of the Smad3
knockout mouse ovaries has revealed that Smad3 defi-
ciency slows follicle growth, causes atretic follicles, degen-
erated oocytes and low expression of the anti-apoptotic
protein bcl-2 [128]. In addition, Smad3 deficiency affects
follicular differentiation as indicated by decreased expres-
sion of estrogen receptor β and inhibin α subunit as well
as increased expression of estrogen receptor α [128]. Estra-
diol levels are low whereas FSH levels are high. The reason
for this discrepancy between the two Smad3 null mouse
lines remains unknown. The knockout mouse for the
inhibitory Smad, Smad6, is also viable but has cardiovas-
cular abnormalities, suggesting a role for Smad6 in the
development and homeostasis of the cardiovascular sys-
tem [129]. Smad7 or Smad8 knockout mice have not been
reported as of yet.
Bristol-Gould et al. recently reported the introduction of a
dominant negative Smad2 gene into mouse gonads [130].
Expression of the transgene under the AMH promotor
directs the expression of this gene to the granulosa cells
and causes subfertility, decreased litter sizes and breeding
frequency in the mutant female mice. The transgenic ova-
ries contain fewer corpora lutea compared to ovaries from
normal littermates and develop multioocytic follicles. In
addition, the transgenic ovaries exhibit symptoms of pre-
mature aging and develop multiple small lesions or inclu-
sion cysts in only three months. The Smad2 dominant
negative transgenic mouse bears resemblance to the
inhibin α-subunit transgenic mouse in being subfertile, as
well as in developing cysts and multioocytic follicles
[131]. The ovarian phenotype of these mice resembles a
human condition known as endosalpingiosis, a pelvic
condition typified by the presence of cystic glandular
structures lined by benign tubal/salpingeal epithelium
supporting a TGF-β/activin/Smad2-dependence in the
onset of this disease [130]. Taken together, it is known
that Smad3 plays a role in folliculogenesis but the role of
other Smads is not so clear since many of the Smad knock-
out mouse models die in utero during early embryonic
development. Generation of tissue-specific conditional
and/or inducible knockout models or the use of RNAi
techniques might be useful in determining the specific
importance of each of the Smads at different stages of fol-
liculogenesis.
Conclusion
Several TGF-β superfamily ligands play important roles in
ovarian organogenesis and the process of folliculogenesis.
Especially the BMPs are prominent during ovarian orga-
nogenesis, whereas folliculogenesis seems to be regulated
by a complex interplay between different GDFs, BMPs and
other TGF-β-like ligands. Some of these ligands are
expressed only within the ovary, such as GDF-9B and
AMH, and also some of their receptors are ovary-specific,
e.g. AMHRII, but most ovarian expressed growth factors
have diverse roles in other tissues as well. Smads, how-
ever, are ubiquitously expressed in nearly all cell types in
the body. Therefore the ovary-specific Smad-interacting
proteins, such as transcription factors and co-modulators,
may play a prominent role in the TGF-β superfamily lig-
and target gene selection in the ovary. The family of Smad
proteins was discovered 10 years ago but we are still in the
early days of understanding Smad function in the ovary
and in fertility. There is the possibility for research into the
development of small molecule drugs against the Smads
and their interacting partners, and it would be interesting
to see in the future if these molecules would affect the dif-
ferent stages of follicle development and whether they
could be used to treat infertility.
Note added in proof: A very recent paper by Massague et al.
provides an excellent review on the role of Smads as tran-
scription factors (Massague et al., Smad transcription fac-
tors. Genes Dev 2005, 19:2783–810).Page 9 of 13
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4:21 http://www.rbej.com/content/4/1/21Additional material
Acknowledgements
The authors of this minireview want to thank Helsinki Biomedical Graduate 
School, Jalmari and Rauha Ahokas Foundation and Helsinki Graduate 
School in Biotechnology and Molecular biology for supporting this work. 
We also thank Dr. Robert Gilchrist for carefully reading this manuscript.
GoCore 5.0, http://www.helsinki.fi/project/ritvos/GoCore/
References
1. Pangas SA, Matzuk MM: Genetic models for transforming
growth factor beta superfamily signaling in ovarian follicle
development.  Mol Cell Endocrinol 2004, 225(1-2):83-91.
2. Yi SE, LaPolt PS, Yoon BS, Chen JY, Lu JK, Lyons KM: The type I
BMP receptor BmprIB is essential for female reproductive
function.  Proc Natl Acad Sci U S A 2001, 98(14):7994-7999.
3. Ying Y, Qi X, Zhao GQ: Induction of primordial germ cells from
murine epiblasts by synergistic action of BMP4 and BMP8B
signaling pathways.  Proc Natl Acad Sci U S A 2001,
98(14):7858-7862.
4. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM:
Genetic characterization and cloning of mothers against
dpp, a gene required for decapentaplegic function in Dro-
sophila melanogaster.  Genetics 1995, 139(3):1347-1358.
5. Derynck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massague
J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Smith J, Thomsen
GH, Vogelstein B, Wang XF: Nomenclature: vertebrate media-
tors of TGFbeta family signals.  Cell 1996, 87(2):173.
6. Masuyama N, Hanafusa H, Kusakabe M, Shibuya H, Nishida E: Identi-
fication of two Smad4 proteins in Xenopus. Their common
and distinct properties.  J Biol Chem 1999, 274(17):12163-12170.
7. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell
membrane to the nucleus.  Cell 2003, 113(6):685-700.
8. Moustakas A, Souchelnytskyi S, Heldin CH: Smad regulation in
TGF-beta signal transduction.  J Cell Sci 2001, 114(Pt
24):4359-4369.
9. Attisano L, Wrana JL: Signal transduction by the TGF-beta
superfamily.  Science 2002, 296(5573):1646-1647.
10. Eppig JJ: Oocyte control of ovarian follicular development and
function in mammals.  Reproduction 2001, 122(6):829-838.
11. Gilchrist RB, Ritter LJ, Armstrong DT: Oocyte-somatic cell inter-
actions during follicle development in mammals.  Anim Reprod
Sci 2004, 82-83:431-446.
12. Tremblay KD, Dunn NR, Robertson EJ: Mouse embryos lacking
Smad1 signals display defects in extra-embryonic tissues and
germ cell formation.  Development 2001, 128(18):3609-3621.
13. Chang H, Matzuk MM: Smad5 is required for mouse primordial
germ cell development.  Mech Dev 2001, 104(1-2):61-67.
14. Xu J, Oakley J, McGee EA: Stage-specific expression of Smad2
and Smad3 during folliculogenesis.  Biol Reprod 2002,
66(6):1571-1578.
15. Dennler S, Huet S, Gauthier JM: A short amino-acid sequence in
MH1 domain is responsible for functional differences
between Smad2 and Smad3.  Oncogene 1999, 18(8):1643-1648.
16. Dunn NR, Koonce CH, Anderson DC, Islam A, Bikoff EK, Robertson
EJ: Mice exclusively expressing the short isoform of Smad2
develop normally and are viable and fertile.  Genes Dev 2005,
19(1):152-163.
17. Hata A, Lo RS, Wotton D, Lagna G, Massague J: Mutations increas-
ing autoinhibition inactivate tumour suppressors Smad2 and
Smad4.  Nature 1997, 388(6637):82-87.
18. Kretzschmar M, Doody J, Massague J: Opposing BMP and EGF sig-
nalling pathways converge on the TGF-beta family mediator
Smad1.  Nature 1997, 389(6651):618-622.
19. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A: Inactiva-
tion of smad-transforming growth factor beta signaling by
Ca(2+)-calmodulin-dependent protein kinase II.  Mol Cell Biol
2000, 20(21):8103-8111.
20. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S: Regulation
of Smad signaling by protein kinase C.  Faseb J 2001,
15(3):553-555.
21. Izzi L, Attisano L: Regulation of the TGFbeta signalling path-
way by ubiquitin-mediated degradation.  Oncogene 2004,
23(11):2071-2078.
22. Fukuchi M, Imamura T, Chiba T, Ebisawa T, Kawabata M, Tanaka K,
Miyazono K: Ligand-dependent degradation of Smad3 by a
ubiquitin ligase complex of ROC1 and associated proteins.
Mol Biol Cell 2001, 12(5):1431-1443.
23. Watanabe M, Masuyama N, Fukuda M, Nishida E: Regulation of
intracellular dynamics of Smad4 by its leucine-rich nuclear
export signal.  EMBO Rep 2000, 1(2):176-182.
24. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS,
Shioda T, Roberts AB, Lechleider RJ: The Smad4 activation
domain (SAD) is a proline-rich, p300-dependent transcrip-
tional activation domain.  J Biol Chem 2000, 275(3):2115-2122.
25. Itoh F, Asao H, Sugamura K, Heldin CH, ten Dijke P, Itoh S: Promot-
ing bone morphogenetic protein signaling through negative
regulation of inhibitory Smads.  Embo J 2001, 20(15):4132-4142.
26. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE,
ten Dijke P: Transforming growth factor beta1 induces
nuclear export of inhibitory Smad7.  J Biol Chem 1998,
273(44):29195-29201.
27. Pierreux CE, Nicolas FJ, Hill CS: Transforming growth factor
beta-independent shuttling of Smad4 between the cyto-
plasm and nucleus.  Mol Cell Biol 2000, 20(23):9041-9054.
28. Dong C, Li Z, Alvarez RJ, Feng XH, Goldschmidt-Clermont PJ:
Microtubule binding to Smads may regulate TGF beta activ-
ity.  Mol Cell 2000, 5(1):27-34.
29. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K: Filamin associ-
ates with Smads and regulates transforming growth factor-
beta signaling.  J Biol Chem 2001, 276(21):17871-17877.
30. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, Massague J:
Determinants of specificity in TGF-beta signal transduction.
Genes Dev 1998, 12(14):2144-2152.
31. Persson U, Izumi H, Souchelnytskyi S, Itoh S, Grimsby S, Engstrom U,
Heldin CH, Funa K, ten Dijke P: The L45 loop in type I receptors
for TGF-beta family members is a critical determinant in
specifying Smad isoform activation.  FEBS Lett 1998, 434(1-
2):83-87.
32. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL: Distinct
endocytic pathways regulate TGF-beta receptor signalling
and turnover.  Nat Cell Biol 2003, 5(5):410-421.
Additional File 1
GoCore v 5.0.1 http://www.helsinki.fi/project/ritvos/GoCore/ summary of 
an alignment of ninety-one Smad sequences, representing eight Smad pro-
teins across seventeen mammalian species. The species included are H. 
sapiens, P. troglodytes, P. anubis, P. pygmaeus, M. mulatta, C. familiaris, 
S. scrofa, B. taurus, O. aries, E. caballus, L. africana, R. norvegicus, M. 
musculus, E. telfairi, D. novemcinctus, M. vison, and O. cuniculus. 
Where sequence variants exist, the longest variants are included. For clar-
ity, the summary is superimposed upon the human sequences. Dark grey 
shading represents a region of 120 residues in the alignment that only 
exist in the inhibitory Smads and is not displayed. Light grey residues in 
Smad2 represent the exon 3 insertion splice variant. Other shading repre-
sents residues that are found uniquely conserved in particular groups of 
Smads across at least 80% of the tested species. Unique, conserved resi-
dues are shaded dark blue for the group of Smads 1, 5 and 8, dark green 
for Smads 2 and 3, light blue for all receptor-mediated Smads, light green 
for all non-inhibitory Smads, tan for all inhibitory Smads, orange for all 
Smads except Smad7, and yellow for all Smads. The MH1 and MH2 
domains are boxed in black and labelled accordingly. The L3 loop in the 
MH2 domain is boxed in blue, and the PY motifs in the linker region are 
boxed in red.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7827-4-21-S1.png]Page 10 of 13
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4:21 http://www.rbej.com/content/4/1/2133. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a
FYVE domain protein that recruits Smad2 to the TGFbeta
receptor.  Cell 1998, 95(6):779-791.
34. Lin HK, Bergmann S, Pandolfi PP: Cytoplasmic PML function in
TGF-beta signalling.  Nature 2004, 431(7005):205-211.
35. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura
Y, Kikuchi A, Miyazono K, Kato M: Axin facilitates Smad3 activa-
tion in the transforming growth factor beta signaling path-
way.  Mol Cell Biol 2001, 21(15):5132-5141.
36. Hocevar BA, Smine A, Xu XX, Howe PH: The adaptor molecule
Disabled-2 links the transforming growth factor beta recep-
tors to the Smad pathway.  Embo J 2001, 20(11):2789-2801.
37. Runyan CE, Schnaper HW, Poncelet AC: The role of internaliza-
tion in transforming growth factor beta1-induced Smad2
association with Smad anchor for receptor activation
(SARA) and Smad2-dependent signaling in human mesangial
cells.  J Biol Chem 2005, 280(9):8300-8308.
38. Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K: The
L3 loop and C-terminal phosphorylation jointly define Smad
protein trimerization.  Nat Struct Biol 2001, 8(3):248-253.
39. Wu JW, Fairman R, Penry J, Shi Y: Formation of a stable het-
erodimer between Smad2 and Smad4.  J Biol Chem 2001,
276(23):20688-20694.
40. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague
J, Niehrs C: Silencing of TGF-beta signalling by the pseudore-
ceptor BAMBI.  Nature 1999, 401(6752):480-485.
41. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH: A SMAD
ubiquitin ligase targets the BMP pathway and affects embry-
onic pattern formation.  Nature 1999, 400(6745):687-693.
42. Lin X, Liang M, Feng XH: Smurf2 is a ubiquitin E3 ligase mediat-
ing proteasome-dependent degradation of Smad2 in trans-
forming growth factor-beta signaling.  J Biol Chem 2000,
275(47):36818-36822.
43. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R:
Regulation of Smad degradation and activity by Smurf2, an
E3 ubiquitin ligase.  Proc Natl Acad Sci U S A 2001, 98(3):974-979.
44. Massague J: How cells read TGF-beta signals.  Nat Rev Mol Cell
Biol 2000, 1(3):169-178.
45. Derynck R, Zhang YE: Smad-dependent and Smad-independ-
ent pathways in TGF-beta family signalling.  Nature 2003,
425(6958):577-584.
46. Liu X, Sun Y, Weinberg RA, Lodish HF: Ski/Sno and TGF-beta sig-
naling.  Cytokine Growth Factor Rev 2001, 12(1):1-8.
47. Kretzschmar M, Doody J, Timokhina I, Massague J: A mechanism of
repression of TGFbeta/ Smad signaling by oncogenic Ras.
Genes Dev 1999, 13(7):804-816.
48. Brown JD, DiChiara MR, Anderson KR, Gimbrone MAJ, Topper JN:
MEKK-1, a component of the stress (stress-activated protein
kinase/c-Jun N-terminal kinase) pathway, can selectively
activate Smad2-mediated transcriptional activation in
endothelial cells.  J Biol Chem 1999, 274(13):8797-8805.
49. Pulaski L, Landstrom M, Heldin CH, Souchelnytskyi S: Phosphoryla-
tion of Smad7 at Ser-249 does not interfere with its inhibi-
tory role in transforming growth factor-beta-dependent
signaling but affects Smad7-dependent transcriptional acti-
vation.  J Biol Chem 2001, 276(17):14344-14349.
50. Saitou M, Payer B, Lange UC, Erhardt S, Barton SC, Surani MA: Spec-
ification of germ cell fate in mice.  Philos Trans R Soc Lond B Biol
Sci 2003, 358(1436):1363-1370.
51. van den Hurk R, Zhao J: Formation of mammalian oocytes and
their growth, differentiation and maturation within ovarian
follicles.  Theriogenology 2005, 63(6):1717-1751.
52. Chuva de Sousa Lopes SM, van den Driesche S, Carvalho RL, Larsson
J, Eggen B, Surani MA, Mummery CL: Altered primordial germ
cell migration in the absence of transforming growth factor
beta signaling via ALK5.  Dev Biol 2005, 284(1):194-203.
53. Gougeon A: Regulation of ovarian follicular development in
primates: facts and hypotheses.  Endocr Rev 1996, 17(2):121-155.
54. Matzuk MM, Burns KH, Viveiros MM, Eppig JJ: Intercellular com-
munication in the mammalian ovary: oocytes carry the con-
versation.  Science 2002, 296(5576):2178-2180.
55. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM: The
bone morphogenetic protein 15 gene is X-linked and
expressed in oocytes.  Mol Endocrinol 1998, 12(12):1809-1817.
56. Laitinen M, Vuojolainen K, Jaatinen R, Ketola I, Aaltonen J, Lehtonen
E, Heikinheimo M, Ritvos O: A novel growth differentiation fac-
tor-9 (GDF-9) related factor is co-expressed with GDF-9 in
mouse oocytes during folliculogenesis.  Mech Dev 1998, 78(1-
2):135-140.
57. Schmid P, Cox D, van der Putten H, McMaster GK, Bilbe G: Expres-
sion of TGF-beta s and TGF-beta type II receptor mRNAs in
mouse folliculogenesis: stored maternal TGF-beta 2 mes-
sage in oocytes.  Biochem Biophys Res Commun 1994,
201(2):649-656.
58. Lyons KM, Pelton RW, Hogan BL: Patterns of expression of
murine Vgr-1 and BMP-2a RNA suggest that transforming
growth factor-beta-like genes coordinately regulate aspects
of embryonic development.  Genes Dev 1989, 3(11):1657-1668.
59. Gilchrist RB, Morrissey MP, Ritter LJ, Armstrong DT: Comparison
of oocyte factors and transforming growth factor-beta in the
regulation of DNA synthesis in bovine granulosa cells.  Mol
Cell Endocrinol 2003, 201(1-2):87-95.
60. Knight PG, Glister C: Local roles of TGF-beta superfamily
members in the control of ovarian follicle development.  Anim
Reprod Sci 2003, 78(3-4):165-183.
61. Liao WX, Moore RK, Shimasaki S: Functional and molecular
characterization of naturally occurring mutations in the
oocyte-secreted factors bone morphogenetic protein-15 and
growth and differentiation factor-9.  J Biol Chem 2004,
279(17):17391-17396.
62. Tomic D, Brodie SG, Deng C, Hickey RJ, Babus JK, Malkas LH, Flaws
JA: Smad 3 may regulate follicular growth in the mouse
ovary.  Biol Reprod 2002, 66(4):917-923.
63. Ingman WV, Robker RL, Woittiez K, Robertson SA: Null mutation
in TGF{beta}1 disrupts ovarian function and causes oocyte
incompetence and early embryo arrest.  Endocrinology 2005.
64. McGrath SA, Esquela AF, Lee SJ: Oocyte-specific expression of
growth/differentiation factor-9.  Mol Endocrinol 1995,
9(1):131-136.
65. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM:
Growth differentiation factor-9 is required during early ovar-
ian folliculogenesis.  Nature 1996, 383(6600):531-535.
66. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL,
Jokiranta TS, McLaren RJ, Luiro K, Dodds KG, Montgomery GW,
Beattie AE, Davis GH, Ritvos O: Mutations in an oocyte-derived
growth factor gene (BMP15) cause increased ovulation rate
and infertility in a dosage-sensitive manner.  Nat Genet 2000,
25(3):279-283.
67. Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R,
Galloway SM: Mutations in the genes for oocyte-derived
growth factors GDF9 and BMP15 are associated with both
increased ovulation rate and sterility in Cambridge and Bel-
clare sheep (Ovis aries).  Biol Reprod 2004, 70(4):900-909.
68. Yan C, Wang P, DeMayo J, DeMayo FJ, Elvin JA, Carino C, Prasad SV,
Skinner SS, Dunbar BS, Dube JL, Celeste AJ, Matzuk MM: Synergistic
roles of bone morphogenetic protein 15 and growth differen-
tiation factor 9 in ovarian function.  Mol Endocrinol 2001,
15(6):854-866.
69. McNatty KP, Galloway SM, Wilson T, Smith P, Hudson NL, O'Connell
A, Bibby AH, Heath DA, Davis GH, Hanrahan JP, Juengel JL: Physio-
logical effects of major genes affecting ovulation rate in
sheep.  Genet Sel Evol 2005, 37 Suppl 1:S25-38.
70. Galloway SM, Gregan SM, Wilson T, McNatty KP, Juengel JL, Ritvos
O, Davis GH: Bmp15 mutations and ovarian function.  Mol Cell
Endocrinol 2002, 191(1):15-18.
71. Hayashi M, McGee EA, Min G, Klein C, Rose UM, van Duin M, Hsueh
AJ: Recombinant growth differentiation factor-9 (GDF-9)
enhances growth and differentiation of cultured early ovar-
ian follicles.  Endocrinology 1999, 140(3):1236-1244.
72. Elvin JA, Clark AT, Wang P, Wolfman NM, Matzuk MM: Paracrine
actions of growth differentiation factor-9 in the mammalian
ovary.  Mol Endocrinol 1999, 13(6):1035-1048.
73. Vitt UA, Hayashi M, Klein C, Hsueh AJ: Growth differentiation
factor-9 stimulates proliferation but suppresses the follicle-
stimulating hormone-induced differentiation of cultured
granulosa cells from small antral and preovulatory rat folli-
cles.  Biol Reprod 2000, 62(2):370-377.
74. Gilchrist RB, Ritter LJ, Cranfield M, Jeffery LA, Amato F, Scott SJ, Myl-
lymaa S, Kaivo-Oja N, Lankinen H, Mottershead DG, Groome NP,
Ritvos O: Immunoneutralization of growth differentiation
factor 9 reveals it partially accounts for mouse oocyte
mitogenic activity.  Biol Reprod 2004, 71(3):732-739.Page 11 of 13
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4:21 http://www.rbej.com/content/4/1/2175. Dragovic RA, Ritter LJ, Schulz SJ, Amato F, Armstrong DT, Gilchrist
RB: Role of oocyte-secreted growth differentiation factor 9 in
the regulation of mouse cumulus expansion.  Endocrinology
2005, 146(6):2798-2806.
76. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, Byrne
MC, Matzuk MM: Knockout of pentraxin 3, a downstream tar-
get of growth differentiation factor-9, causes female subfer-
tility.  Mol Endocrinol 2002, 16(6):1154-1167.
77. Pangas SA, Jorgez CJ, Matzuk MM: Growth differentiation factor
9 regulates expression of the bone morphogenetic protein
antagonist gremlin.  J Biol Chem 2004, 279(31):32281-32286.
78. Vitt UA, McGee EA, Hayashi M, Hsueh AJ: In vivo treatment with
GDF-9 stimulates primordial and primary follicle progres-
sion and theca cell marker CYP17 in ovaries of immature
rats.  Endocrinology 2000, 141(10):3814-3820.
79. Solovyeva EV, Hayashi M, Margi K, Barkats C, Klein C, Amsterdam A,
Hsueh AJ, Tsafriri A: Growth differentiation factor-9 stimulates
rat theca-interstitial cell androgen biosynthesis.  Biol Reprod
2000, 63(4):1214-1218.
80. Yamamoto N, Christenson LK, McAllister JM, Strauss JF: Growth
differentiation factor-9 inhibits 3'5'-adenosine monophos-
phate-stimulated steroidogenesis in human granulosa and
theca cells.  J Clin Endocrinol Metab 2002, 87(6):2849-2856.
81. Otsuka F, Yamamoto S, Erickson GF, Shimasaki S: Bone morphoge-
netic protein-15 inhibits follicle-stimulating hormone (FSH)
action by suppressing FSH receptor expression.  J Biol Chem
2001, 276(14):11387-11392.
82. Otsuka F, Shimasaki S: A negative feedback system between
oocyte bone morphogenetic protein 15 and granulosa cell kit
ligand: its role in regulating granulosa cell mitosis.  Proc Natl
Acad Sci U S A 2002, 99(12):8060-8065.
83. Hussein TS, Froiland DA, Amato F, Thompson JG, Gilchrist RB:
Oocytes prevent cumulus cell apoptosis by maintaining a
morphogenic paracrine gradient of bone morphogenetic
proteins.  J Cell Sci 2005.
84. McNatty KP, Juengel JL, Reader KL, Lun S, Myllymaa S, Lawrence SB,
Western A, Meerasahib MF, Mottershead DG, Groome NP, Ritvos
O, Laitinen MP: Bone morphogenetic protein 15 and growth
differentiation factor 9 co-operate to regulate granulosa cell
function in ruminants.  Reproduction 2005, 129(4):481-487.
85. McNatty KP, Juengel JL, Reader KL, Lun S, Myllymaa S, Lawrence SB,
Western A, Meerasahib MF, Mottershead DG, Groome NP, Ritvos
O, Laitinen MP: Bone morphogenetic protein 15 and growth
differentiation factor 9 co-operate to regulate granulosa cell
function.  Reproduction 2005, 129(4):473-480.
86. Mazerbourg S, Klein C, Roh J, Kaivo-Oja N, Mottershead DG,
Korchynskyi O, Ritvos O, Hsueh AJ: Growth differentiation fac-
tor-9 signaling is mediated by the type I receptor, activin
receptor-like kinase 5.  Mol Endocrinol 2004, 18(3):653-665.
87. Roh JS, Bondestam J, Mazerbourg S, Kaivo-Oja N, Groome N, Ritvos
O, Hsueh AJ: Growth differentiation factor-9 stimulates
inhibin production and activates Smad2 in cultured rat gran-
ulosa cells.  Endocrinology 2003, 144(1):172-178.
88. Vitt UA, Mazerbourg S, Klein C, Hsueh AJ: Bone morphogenetic
protein receptor type II is a receptor for growth differentia-
tion factor-9.  Biol Reprod 2002, 67(2):473-480.
89. Kaivo-Oja N, Bondestam J, Kamarainen M, Koskimies J, Vitt U, Cran-
field M, Vuojolainen K, Kallio JP, Olkkonen VM, Hayashi M, Moustakas
A, Groome NP, ten Dijke P, Hsueh AJ, Ritvos O: Growth differen-
tiation factor-9 induces Smad2 activation and inhibin B pro-
duction in cultured human granulosa-luteal cells.  J Clin
Endocrinol Metab 2003, 88(2):755-762.
90. Kaivo-Oja N, Mottershead DG, Mazerbourg S, Myllymaa S, Duprat S,
Gilchrist RB, Groome NP, Hsueh AJ, Ritvos O: Adenoviral gene
transfer allows Smad-responsive gene promoter analyses
and delineation of type I receptor usage of transforming
growth factor-beta family ligands in cultured human granu-
losa luteal cells.  J Clin Endocrinol Metab 2005, 90(1):271-278.
91. Moore RK, Otsuka F, Shimasaki S: Molecular basis of bone mor-
phogenetic protein-15 signaling in granulosa cells.  J Biol Chem
2003, 278(1):304-310.
92. McNatty KP, Juengel JL, Wilson T, Galloway SM, Davis GH: Genetic
mutations influencing ovulation rate in sheep.  Reprod Fertil Dev
2001, 13(7-8):549-555.
93. Otsuka F, Moore RK, Shimasaki S: Biological function and cellular
mechanism of bone morphogenetic protein-6 in the ovary.  J
Biol Chem 2001, 276(35):32889-32895.
94. de Caestecker M: The transforming growth factor-beta super-
family of receptors.  Cytokine Growth Factor Rev 2004, 15(1):1-11.
95. Shimasaki S, Moore RK, Otsuka F, Erickson GF: The bone morpho-
genetic protein system in mammalian reproduction.  Endocr
Rev 2004, 25(1):72-101.
96. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M,
Miyazono K, Imamura T: Characterization of bone morphoge-
netic protein-6 signaling pathways in osteoblast differentia-
tion.  J Cell Sci 1999, 112 ( Pt 20):3519-3527.
97. Teixeira Filho FL, Baracat EC, Lee TH, Suh CS, Matsui M, Chang RJ,
Shimasaki S, Erickson GF: Aberrant expression of growth differ-
entiation factor-9 in oocytes of women with polycystic ovary
syndrome.  J Clin Endocrinol Metab 2002, 87(3):1337-1344.
98. Rabinovici J, Spencer SJ, Jaffe RB: Recombinant human activin-A
promotes proliferation of human luteinized preovulatory
granulosa cells in vitro.  J Clin Endocrinol Metab 1990,
71(5):1396-1398.
99. Xiao S, Robertson DM, Findlay JK: Effects of activin and follicle-
stimulating hormone (FSH)-suppressing protein/follistatin
on FSH receptors and differentiation of cultured rat granu-
losa cells.  Endocrinology 1992, 131(3):1009-1016.
100. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian
LM, Vale W: Betaglycan binds inhibin and can mediate func-
tional antagonism of activin signalling.  Nature 2000,
404(6776):411-414.
101. Gray PC, Harrison CA, Vale W: Cripto forms a complex with
activin and type II activin receptors and can block activin sig-
naling.  Proc Natl Acad Sci U S A 2003, 100(9):5193-5198.
102. Erickson GF, Shimasaki S: The spatiotemporal expression pat-
tern of the bone morphogenetic protein family in rat ovary
cell types during the estrous cycle.  Reprod Biol Endocrinol 2003,
1:9.
103. Jaatinen R, Rosen V, Tuuri T, Ritvos O: Identification of ovarian
granulosa cells as a novel site of expression for bone mor-
phogenetic protein-3 (BMP-3/osteogenin) and regulation of
BMP-3 messenger ribonucleic acids by chorionic gonadotro-
pin in cultured human granulosa-luteal cells.  J Clin Endocrinol
Metab 1996, 81(11):3877-3882.
104. Souza CJ, Campbell BK, McNeilly AS, Baird DT: Effect of bone
morphogenetic protein 2 (BMP2) on oestradiol and inhibin A
production by sheep granulosa cells, and localization of BMP
receptors in the ovary by immunohistochemistry.  Reproduc-
tion 2002, 123(3):363-369.
105. Jaatinen R, Bondestam J, Raivio T, Hilden K, Dunkel L, Groome N,
Ritvos O: Activation of the bone morphogenetic protein sign-
aling pathway induces inhibin beta(B)-subunit mRNA and
secreted inhibin B levels in cultured human granulosa-luteal
cells.  J Clin Endocrinol Metab 2002, 87(3):1254-1261.
106. Gamer LW, Nove J, Levin M, Rosen V: BMP-3 is a novel inhibitor
of both activin and BMP-4 signaling in Xenopus embryos.  Dev
Biol 2005, 285(1):156-168.
107. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nach-
tigal MW, Uilenbroek JT, Grootegoed JA, Themmen AP: Anti-Mul-
lerian hormone inhibits initiation of primordial follicle
growth in the mouse ovary.  Endocrinology 2002,
143(3):1076-1084.
108. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Groo-
tegoed JA, Themmen AP: Control of primordial follicle recruit-
ment by anti-Mullerian hormone in the mouse ovary.
Endocrinology 1999, 140(12):5789-5796.
109. McGee EA, Smith R, Spears N, Nachtigal MW, Ingraham H, Hsueh AJ:
Mullerian inhibitory substance induces growth of rat preant-
ral ovarian follicles.  Biol Reprod 2001, 64(1):293-298.
110. Schmidt KL, Kryger-Baggesen N, Byskov AG, Andersen CY: Anti-
Mullerian hormone initiates growth of human primordial fol-
licles in vitro.  Mol Cell Endocrinol 2005, 234(1-2):87-93.
111. Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hooger-
brugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Mei-
jers JH, et al.: A novel member of the transmembrane serine/
threonine kinase receptor family is specifically expressed in
the gonads and in mesenchymal cells adjacent to the mulle-
rian duct.  Development 1994, 120(1):189-197.Page 12 of 13
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2006, 4:21 http://www.rbej.com/content/4/1/21Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
112. Dutertre M, Gouedard L, Xavier F, Long WQ, di Clemente N, Picard
JY, Rey R: Ovarian granulosa cell tumors express a functional
membrane receptor for anti-Mullerian hormone in trans-
genic mice.  Endocrinology 2001, 142(9):4040-4046.
113. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingra-
ham HA: The serine/threonine transmembrane receptor
ALK2 mediates Mullerian inhibiting substance signaling.  Mol
Endocrinol 2001, 15(6):936-945.
114. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I,
Josso N, Massague J, di Clemente N: Engagement of bone mor-
phogenetic protein type IB receptor and Smad1 signaling by
anti-Mullerian hormone and its type II receptor.  J Biol Chem
2000, 275(36):27973-27978.
115. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR: Require-
ment of Bmpr1a for Mullerian duct regression during male
sexual development.  Nat Genet 2002, 32(3):408-410.
116. Shimasaki S, Zachow RJ, Li D, Kim H, Iemura S, Ueno N, Sampath K,
Chang RJ, Erickson GF: A functional bone morphogenetic pro-
tein system in the ovary.  Proc Natl Acad Sci U S A 1999,
96(13):7282-7287.
117. Ghiglieri C, Khatchadourian C, Tabone E, Hendrick JC, Benahmed M,
Menezo Y: Immunolocalization of transforming growth fac-
tor-beta 1 and transforming growth factor-beta 2 in the
mouse ovary during gonadotrophin-induced follicular matu-
ration.  Hum Reprod 1995, 10(8):2115-2119.
118. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL: Spe-
cific activation of Smad1 signaling pathways by the BMP7
type I receptor, ALK2.  J Biol Chem 1998, 273(40):25628-25636.
119. Pangas SA, Rademaker AW, Fishman DA, Woodruff TK: Localiza-
tion of the activin signal transduction components in normal
human ovarian follicles: implications for autocrine and para-
crine signaling in the ovary.  J Clin Endocrinol Metab 2002,
87(6):2644-2657.
120. Lechleider RJ, Ryan JL, Garrett L, Eng C, Deng C, Wynshaw-Boris A,
Roberts AB: Targeted mutagenesis of Smad1 reveals an
essential role in chorioallantoic fusion.  Dev Biol 2001,
240(1):157-167.
121. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX: Failure of egg
cylinder elongation and mesoderm induction in mouse
embryos lacking the tumor suppressor smad2.  Proc Natl Acad
Sci U S A 1998, 95(16):9378-9383.
122. Nomura M, Li E: Smad2 role in mesoderm formation, left-right
patterning and craniofacial development.  Nature 1998,
393(6687):786-790.
123. Sirard C, de la Pompa JL, Elia A, Itie A, Mirtsos C, Cheung A, Hahn S,
Wakeham A, Schwartz L, Kern SE, Rossant J, Mak TW: The tumor
suppressor gene Smad4/Dpc4 is required for gastrulation
and later for anterior development of the mouse embryo.
Genes Dev 1998, 12(1):107-119.
124. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwi-
jsen A: Smad5 knockout mice die at mid-gestation due to
multiple embryonic and extraembryonic defects.  Develop-
ment 1999, 126(8):1631-1642.
125. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE,
Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB: Mice
lacking Smad3 show accelerated wound healing and an
impaired local inflammatory response.  Nat Cell Biol 1999,
1(5):260-266.
126. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts
AB, Deng C: Targeted disruption of SMAD3 results in
impaired mucosal immunity and diminished T cell respon-
siveness to TGF-beta.  Embo J 1999, 18(5):1280-1291.
127. Zhu Y, Richardson JA, Parada LF, Graff JM: Smad3 mutant mice
develop metastatic colorectal cancer.  Cell 1998,
94(6):703-714.
128. Tomic D, Miller KP, Kenny HA, Woodruff TK, Hoyer P, Flaws JA:
Ovarian follicle development requires Smad3.  Mol Endocrinol
2004, 18(9):2224-2240.
129. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN,
Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MAJ, Falb D,
Huszar D: A role for smad6 in development and homeostasis
of the cardiovascular system.  Nat Genet 2000, 24(2):171-174.
130. Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Wood-
ruff TK: The Development of a Mouse Model of Ovarian
Endosalpingiosis.  Endocrinology 2005.
131. McMullen ML, Cho BN, Yates CJ, Mayo KE: Gonadal pathologies
in transgenic mice expressing the rat inhibin alpha-subunit.
Endocrinology 2001, 142(11):5005-5014.
132. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression
cloning of the TGF-beta type II receptor, a functional trans-
membrane serine/threonine kinase.  Cell 1992, 68(4):775-785.
133. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH,
Miyazono K: Cloning of a TGF beta type I receptor that forms
a heteromeric complex with the TGF beta type II receptor.
Cell 1993, 75(4):681-692.
134. Attisano L, Wrana JL, Cheifetz S, Massague J: Novel activin recep-
tors: distinct genes and alternative mRNA splicing generate
a repertoire of serine/threonine kinase receptors.  Cell 1992,
68(1):97-108.
135. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K,
Heldin CH: Characterization of type I receptors for trans-
forming growth factor-beta and activin.  Science 1994,
264(5155):101-104.
136. Mathews LS, Vale WW: Expression cloning of an activin recep-
tor, a predicted transmembrane serine kinase.  Cell 1991,
65(6):973-982.
137. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten
Dijke P, Heldin CH, Miyazono K: Cloning and characterization of
a human type II receptor for bone morphogenetic proteins.
Proc Natl Acad Sci U S A 1995, 92(17):7632-7636.
138. Yamaji N, Celeste AJ, Thies RS, Song JJ, Bernier SM, Goltzman D,
Lyons KM, Nove J, Rosen V, Wozney JM: A mammalian serine/
threonine kinase receptor specifically binds BMP-2 and BMP-
4.  Biochem Biophys Res Commun 1994, 205(3):1944-1951.
139. Shimasaki S, Moore RK, Erickson GF, Otsuka F: The role of bone
morphogenetic proteins in ovarian function.  Reprod Suppl
2003, 61:323-337.
140. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle
DL, Ichijo H, Heldin CH, Miyazono K: Identification of type I
receptors for osteogenic protein-1 and bone morphogenetic
protein-4.  J Biol Chem 1994, 269(25):16985-16988.
141. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M,
Smith JC, Heldin CH, Miyazono K: Osteogenic protein-1 binds to
activin type II receptors and induces certain activin-like
effects.  J Cell Biol 1995, 130(1):217-226.Page 13 of 13
(page number not for citation purposes)
